Transcend Therapeutics

Transcend Therapeutics is a private, New York-based biotech founded in 2021, operating in the psychedelics-derived therapeutics sector. The company has achieved significant clinical and regulatory milestones, including Breakthrough Therapy Designation from the FDA for its lead program, TSND-201, for PTSD, and has recently agreed to be acquired by Otsuka Pharmaceutical. Its strategy centers on developing rapid-acting, neuroplasticity-promoting (neuroplastogen) drugs that offer a novel mechanism of action compared to standard-of-care antidepressants and anxiolytics. With promising Phase 2 data published in a top-tier journal, Transcend is positioned as a key player in the next generation of mental health therapeutics.

Development of novel neuroplastogens targeting the serotonin 2A (5-HT2A) receptor to promote rapid neuroplasticity for treating neuropsychiatric diseases.

Transcend competes in the rapidly evolving psychedelic-inspired medicine space, alongside companies developing psilocybin (e.g., Compass Pathways), MDMA (MAPS PBC), and other 5-HT2A agonists. It also competes with broader neuropsychiatric drug developers. Its differentiation lies in TSND-201's specific pharmacologic profile aiming for rapid efficacy with a potentially more manageable treatment paradigm.